Goodwin Procter advised Garuda Therapeutics on the deal.Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed, and…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
